Ultragenyx’s Phase 3 Angelman Syndrome Trial Fails, Triggering 43% Stock Plunge

September 6, 2026

Fierce Biotech USA

Overview

Ultragenyx reported that its investigational asset apazunersen failed to meet primary and secondary endpoints in the Phase 3 Aspire trial for Angelman syndrome, leading to a dramatic 43% drop in the company’s shares. The company plans to evaluate the future of the apazunersen program and explore cost-cutting measures. This outcome highlights the significant risks and challenges associated with developing treatments for rare neurological disorders.

In Depth

Background

Angelman syndrome is a complex genetic disorder primarily affecting the nervous system, characterized by developmental delays, intellectual disability, severe speech impairment, and problems with movement and balance. Given its rarity and profound impact, effective treatments are urgently needed. Ultragenyx Pharmaceutical has been developing apazunersen, an investigational asset, to address this unmet medical need, progressing it into a pivotal Phase 3 clinical trial named Aspire.

Key Findings

The Phase 3 Aspire trial evaluating apazunersen for Angelman syndrome failed to achieve its primary endpoint.
Furthermore, the trial did not meet any of its secondary endpoints, indicating a lack of significant clinical benefit.
Following the announcement of these results, Ultragenyx’s stock experienced a sharp decline, plummeting by 43%.
The company stated it would re-evaluate the apazunersen program’s future strategy and consider implementing cost-reduction measures across its operations.

Significance & Outlook

This clinical setback is a significant blow to Ultragenyx and to the Angelman syndrome patient community, who are awaiting therapeutic breakthroughs. The substantial stock market reaction underscores the high-stakes nature of late-stage pharmaceutical development, especially in rare disease indications where patient populations are small and development pathways are often fraught with challenges. The company’s decision to reassess the program and pursue cost-cutting reflects the financial pressures inherent in such failures. This event will likely prompt Ultragenyx to reallocate resources to its other pipeline assets, while the broader rare disease therapeutic landscape continues to grapple with the complexities of bringing novel treatments to market.

Source: https://www.fiercebiotech.com/biotech/ultragenyx-fails-phase-3-angelman-test-plots-significant-expenses-reduction

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.